Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)—multicenter real-world analysis from Germany and comparative review of the literature
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06441-8
Abstract: With the introduction of novel agents (proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), immuntherapeutics), the outcome of multiple myeloma (MM) patients has improved. The oral PI ixazomib was authorized in the EU in 11/2016 and is… read more here.
Keywords: rrmm; multiple myeloma; real world; dexamethasone ird ... See more keywords